Most recently, Sworder et al. observed the emergence of mutations in CD19, PAX5, and TP53 following DLBCL relapse after CAR T-cell therapy, representing candidate resistance mechanisms to this novel therapeutic approach [83]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.